Hepatic Arterial Infusion Chemotherapy (HAIC)-Based Conversion Hepatectomy in Patients with Hepatocellular Carcinoma Academic Background Hepatocellular carcinoma (HCC) is one of the most common liver malignancies worldwide, particularly in China, where its incidence and mortality rates remain high. Despite advancements in treatment strategies, radi...

Evaluation of Treatment Outcomes Using DNLR and GNRI in Combination Therapy for Hepatocellular Carcinoma Background Hepatocellular carcinoma (HCC) is one of the most common malignant tumors worldwide, particularly in Asia. Due to its lack of early symptoms, many patients are diagnosed at an advanced stage, making surgical resection unfeasible. In r...

Inhibition of Liver Acetyl-CoA Carboxylase (ACC) Activity Exacerbates Liver Tumorigenesis in Mice Academic Background Liver cancer is the sixth most common cancer globally and the third leading cause of cancer-related mortality. Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer. In recent years, the burden of liver canc...

The Role of SRSF10 in Immunotherapy for Hepatocellular Carcinoma Academic Background Hepatocellular carcinoma (HCC) ranks sixth in global cancer incidence and third in mortality. Although surgical resection is the primary treatment for HCC, the high postoperative recurrence rate significantly impacts patient prognosis. In recent years, immunotherap...

Academic Background and Problem Statement Fibroblast growth factor receptor inhibitors (FGFRi) are a class of targeted drugs used to treat intrahepatic cholangiocarcinoma (iCCA). Although FGFRi has shown significant efficacy in treating iCCA, the potential complications associated with their long-term use have not been fully studied. In particular,...